环丝氨酸治疗耐多药肺结核的临床疗效及安全性  

Clinical Efficacy and Safety of Cycloserine in the Treatment of MDR-TB

作　　者：李卓 LI Zhuo(No.2 Department of Tuberculosis,Jinzhou Infectious Diseases Hospital,Jinzhou 121000,China)

机构地区：[1]锦州市传染病医院结核内二科,辽宁锦州121000

出　　处：《中国医药指南》2020年第30期115-116,共2页Guide of China Medicine

摘　　要：目的探讨环丝氨酸治疗耐多药肺结核的临床疗效及安全性。方法选取2014年1月至2016年1月在我院就诊的172例耐多药肺结核患者,按就诊先后分成观察组(n=86)与对照组(n=86),对照组采取常规抗结核药物治疗,观察组在对照组基础上予以环丝氨酸治疗,观察两组痰菌阴转率及不良反应情况。结果观察组患者6、9、12、24个月时的痰菌阴转率与对照组相比较无明显统计学差异(P>0.05);观察组患者不良反应发生率为3.49%,低于对照组的11.63%,差异存在统计学意义(P<0.05)。结论环丝氨酸治疗耐多药肺结核的临床疗效显著,可减少不良反应,安全性高。Objective To investigate the clinical effi cacy and safety of cycloserine in the treatment of multi-drug resistant pulmonary tuberculosis(MDRTB).Methods From January 2014 to January 2016,172 patients with MDR-TB in our hospital were divided into observation group(n=86)and control group(n=86).The control group was treated with routine antituberculosis drugs.The observation group was treated with cyclosemide acid on the basis of the control group.The negative conversion rate of sputum bacteria in the two groups was observed.Results There was no signifi cant diff erence in sputum negative conversion rate between the observation group and the control group at 6,9,12 and 24 months(P>0.05);the incidence of adverse reactions in the observation group was 3.49%,lower than that in the control group(11.63%,P<0.05).Conclusion Cycloserine is eff ective in the treatment of multi-drug resistant pulmonary tuberculosis.It can reduce adverse reactions and has high safety.

关 键 词：耐多药肺结核 环丝氨酸 安全性 痰菌阴转率 

分 类 号：R521[医药卫生—内科学]